Physicians interviewed by Rheumatology Advisor recommend using the Clinical Disease Activity Index and to treat-to-target by measuring clinical response and adapting therapy rapidly for patients with rheumatoid arthritis.
Researchers found data that showed in patients with rheumatoid arthritis, the delta-tetrahydrocannabinol found in medical cannabis is likely to contribute to an increase in heart rate in patients who are susceptible to atherosclerosis and cardiovascular disease. Medical cannabis was also not found to provide therapeutic effects when comparing it with a combination of cannabinoid type 1 antagonist, fatty acid amide hydrolase inhibitor, and nonpsychotropic cannabidiol.
Rheumatology Advisor interviewed Dr Sofat, who suggests that better control of periodontal disease might improve outcomes in rheumatoid arthritis.
Ocular symptoms can be the dominant clinical manifestation of rheumatic disease in some cases and knowledge of these relationships can improve the care of both the eye and the joint disease.
Novel nonsurgical treatments for osteoarthritis are being developed, but the benefits of new treatments must be weighed against their cost and potential risks.
Investigators found evidence that both aerobic and resistance training lowers insulin resistance, but further studies are needed to determine the specific effects in patients with rheumatoid arthritis.
Data suggest that patients in remission with baricitinib 4 mg daily dose who have taken this medication for at least 1 year may be able to attempt baricitinib dose-tapering while continuing their methotrexate regimen.
The American College of Rheumatology and the National Psoriasis Foundation have released 2018 joint recommendations for the treatment of psoriatic arthritis.
Many components of diet have been implicated as possible risk factors for RA, with varying degrees of evidence.
Therapeutic drug monitoring may be useful to help clinicians assess nonadherence in patients with SLE.
